| Bioactivity | CUR5g is a potent autophagy inhibitor. CUR5g selectively inhibits autophagosome degradation in cancer cells by blocking autophagosome-lysosome fusion. CUR5g blocks the recruitment of STX17 to autophagosomes via a UVRAG-dependent mechanism, resulting in the inability of autophagosomes to fuse with lysosomes. CUR5g improves the anticancer effect of Cisplatin (HY-17394) against A549 cells both in vitro and in vivo[1]. |
| Invitro | CUR5g (0-40 μM, 0-24 h) 选择性诱导癌细胞自噬体积累[1]。CUR5g（0-40 μM，0-24 小时）上调 LC3B-II 和 sequestosome 1 (SQSTM1) 水平[1]。CUR5g (0-40 μM, 24 h) 抑制 A549 细胞增殖和迁移，但不诱导细胞凋亡或坏死[1]。 Cell Autophagy Assay[1] Cell Line: |
| In Vivo | CUR5g (40 mg/kg，尾静脉注射，每 2 天一次，15 天) 与顺铂(Cisplatin，HY-17394) (1 mg/kg) 具有协同抗癌作用，并抑制体内自噬通量[1]。 Animal Model: |
| Name | CUR5g |
| CAS | 1370032-20-4 |
| Formula | C22H20N2O2 |
| Molar Mass | 344.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen J, et al. CUR5g, a novel autophagy inhibitor, exhibits potent synergistic anticancer effects with cisplatin against non-small-cell lung cancer. Cell Death Discov. 2022 Oct 31;8(1):435. |